Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Free Cash Flow (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Free Cash Flow for 13 consecutive years, with -$28.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 198.2% to -$28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $331.8 million through Dec 2025, up 59.99% year-over-year, with the annual reading at $331.8 million for FY2025, 59.99% up from the prior year.
  • Free Cash Flow hit -$28.1 million in Q4 2025 for Coherus Oncology, up from -$46.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $436.8 million in Q2 2025 to a low of -$100.0 million in Q4 2022.
  • Historically, Free Cash Flow has averaged $4.1 million across 5 years, with a median of -$34.0 million in 2022.
  • Biggest five-year swings in Free Cash Flow: crashed 8343.95% in 2022 and later skyrocketed 355.63% in 2024.
  • Year by year, Free Cash Flow stood at -$52.8 million in 2021, then crashed by 89.51% to -$100.0 million in 2022, then surged by 87.03% to -$13.0 million in 2023, then surged by 320.55% to $28.6 million in 2024, then tumbled by 198.2% to -$28.1 million in 2025.
  • Business Quant data shows Free Cash Flow for CHRS at -$28.1 million in Q4 2025, -$46.3 million in Q3 2025, and $436.8 million in Q2 2025.